Evidence map›Paper›PMID 28978044›Full record

ArticleOncotarget2017

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.

Sonja I Buschow, Matteo Ramazzotti, Inge M J Reinieren-Beeren, Lucie M Heinzerling, Harm Westdorp, Irene Stefanini, Luca Beltrame, Stanleyson V Hato, Eva Ellebaek, Stefanie Gross and 12 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. The YYR (YY1- RKIP) Regulatory Axis in the pathogenesis of Cancer and Immune Evasion.Journal of experimental & clinical cancer research : CR · 2025
    Review
  3. Article
  4. Review
  5. Combining chemotherapy and autologous peptide-pulsed dendritic cells provides survival benefit in stage IV melanoma patients.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2020
    Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 11 institutions in 7 countries.

Sonja I Buschow *Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Matteo Ramazzotti *Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Inge M J Reinieren-BeerenDepartment of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Lucie M HeinzerlingDepartment of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany.
Harm WestdorpDepartment of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Irene StefaniniDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Luca BeltrameDepartment of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Stanleyson V HatoDepartment of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Eva EllebaekCCIT, Center for Cancer Immune Therapy, Department of Hematology and Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
Stefanie GrossDepartment of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany.
Van Anh NguyenDepartment of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.
Georg WeinlichDepartment of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.
Jiannis RagoussisGenomics Group, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
Dilair BabanGenomics Group, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
Beatrice Schuler-ThurnerDepartment of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany.
Inge M SvaneCCIT, Center for Cancer Immune Therapy, Department of Hematology and Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
Nikolaus RomaniDepartment of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.
Jonathan M AustynNuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
I Jolanda M De VriesDepartment of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Gerold Schuler *Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany.
Duccio Cavalieri *Department of Biology, University of Florence, Firenze, Italy.
Carl G Figdor *Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DERadboud University Medical Center · NLRadboud University Nijmegen · NLUniversity of Florence · ITCentre for Human Genetics · GBCopenhagen University Hospital · DKUniversität Innsbruck · ATInnsbruck Medical University · ATMario Negri Institute for Pharmacological Research · ITUniversitätsklinikum Erlangen · DEUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy for metastatic melanoma offers great promise but, to date, only a subset of patients have responded. There is an urgent need to identify ways of allocating patients to the most beneficial therapy, to increase survival and decrease therapy-associated morbidity and costs. Blood-based biomarkers are of particular interest because of their straightforward implementation in routine clinical care. We sought to identify markers for dendritic cell (DC) vaccine-based immunotherapy against metastatic melanoma through gene expression analysis of peripheral blood mononuclear cells. A large-scale microarray analysis of 74 samples from two treatment centers, taken directly after the first round of DC vaccination, was performed. We found that phosphatidylethanolamine binding protein 1 (

Indexed as

dendritic cell vaccinationimmune suppressionimmunotherapymelanomaPEBP1

Identifiers

PMID28978044
PMCPMC5620184
OpenAlexW2727856228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.